US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,480.06

+12.920.88%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,487.39

Open:1,467.14

Low:1,462.61

Close:1,467.14

Loading ...

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Jim Cramer on Johnson & Johnson (JNJ): ‘This Stock Has Been a Horse!’

Why Moderna Stock Has Surged 20% This Week Despite Mixed News

Moderna call volume above normal and directionally bullish

Neumora Therapeutics Shares Fall 13.8% After Johnson & Johnson Stops Studies of Rival Depression Drug

THOMSON REUTERS

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

Neumora Therapeutics Shares Down 11.2% Premarket After Johnson & Johnson Stops Studies of Rival Depression Drug

THOMSON REUTERS

Stock Market Drama Highlights Trump's Game Of Chicken With Economy

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint

MT Newswires Live

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

2 Dependable Dividend Stocks That Can Pay You for Life

AstraZeneca announces MATTERHORN trial results

Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517464657","title":"Buy Gilead Sciences (GILD) Stock at 52-Week Highs?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517464657","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517464657?lang=en_us&edition=fundamental","pubTime":"2025-03-08 04:54","pubTimestamp":1741380840,"startTime":"0","endTime":"0","summary":"Medical pioneer Gilead Sciences GILDhas seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster of healthcare stocks that have risen to fresh peaks.This makes it a worthy topic of whether Gilead’s stock can reach higher highs with investors scoping out exposure to the medical sector amid economic uncertainty. Trading at $117 a share, GILD has spiked nearly +30% year to date with the broader market indexes in negative territory.Bringing in $28.75 billion in 2024, Gilead’s top line is expected to dip 1% this year but is projected to rebound and rise 4% in fiscal 2026 to $29.7 billion.More intriguing, Gilead’s operational efficiency has led the company and its stock back to prominence. Gilead’s annual earnings are expected to soar 70% in FY25 to $7.87 per share compared to EPS of $4.62 last year. Plus, FY26 EPS is projected to increase another 5%.Gilead Sciences, Inc.  : Free Stock Analysis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-gilead-sciences-gild-stock-205400778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4139","LU0792757196.USD","LU0234570918.USD","LU1430594728.SGD","BK4007","LU0234572021.USD","LU1674673428.USD","BK4588","BK4559","SG9999002232.USD","GILD","LU1894683348.USD","LU0122379950.USD","IE00B7SZLL34.SGD","JNJ","LU2089984988.USD","LU2505996681.GBP","IE00BDGV0183.EUR","LU1914381329.SGD","LU1929549753.HKD","BK4583","LU1057294990.SGD","LU2087621335.USD","LU2112291526.USD","BK4550","BK4585","LU0345769128.USD","BK4568","LU1032955483.USD","LU0203347892.USD","LU2133065610.SGD","LU2430703095.HKD","LU2430703251.USD","LU1244550494.USD","LU0345770993.USD","SG9999002224.SGD","LU0058720904.USD","LU1732800096.USD","BK4532","LU0345769631.USD","LU1585245621.USD","IE0034235303.USD","LU1061106388.HKD","LU1894683264.USD","BK4566","LU1778281490.HKD","IE000M9KFDE8.USD","IE00BKVL7J92.USD","LU1506573853.SGD"],"gpt_icon":0},{"id":"2517455982","title":"Jim Cramer on Johnson & Johnson (JNJ): ‘This Stock Has Been a Horse!’","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455982","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517455982?lang=en_us&edition=fundamental","pubTime":"2025-03-08 01:13","pubTimestamp":1741367632,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Discusses These 13 Stocks & Criticizes Billionaires. In this article, we are going to take a look at where Johnson & Johnson  stands against other stocks that Jim Cramer discusses.In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer continued to warn users to not trust billionaires. His remarks built on an earlier show, where he had shared that “you can’t make money listening to a billionaire because they already have made money.”In response, co-host David Faber pointed out that the one key trait that he has observed in most billionaires is their relentless drive. Cramer responded by sharing that billionaires are “tiresome.” He also felt that President Biden’s goodbye speech about oligarchs was “completely ignored.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-johnson-johnson-jnj-171352384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BVYPNV92.GBP","LU2129689514.USD","IE00B1BXHZ80.USD","LU0203347892.USD","LU1674673691.USD","BK4504","LU2505996509.AUD","LU1244550577.SGD","IE00B2B36J28.USD","LU0345770308.USD","LU1032955483.USD","LU0466842654.USD","LU1061106388.HKD","BK4581","IE00B19Z3581.USD","IE00BDGV0183.EUR","LU0640476718.USD","LU1778281490.HKD","SG9999001440.SGD","JNJ","LU1732800096.USD","LU0345770993.USD","LU1162221912.USD","LU2430703095.HKD","BK4568","LU0882574055.USD","IE00BSNM7G36.USD","BK4559","LU1023059063.AUD","LU0345769128.USD","LU1066051811.HKD","LU2133065610.SGD","BK4534","LU1718418525.SGD","IE00B4R5TH58.HKD","LU0795875086.SGD","LU2430703178.SGD","LU0795875169.SGD","LU1066051498.USD","LU1430594728.SGD","BK4007","IE00B7SZLL34.SGD","LU0098860793.USD","IE00BVYPNW00.USD","LU0289739699.SGD","LU0889566641.SGD","LU1732799900.SGD","BK4588","LU1066053197.SGD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2517621457","title":"Why Moderna Stock Has Surged 20% This Week Despite Mixed News","url":"https://stock-news.laohu8.com/highlight/detail?id=2517621457","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517621457?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:58","pubTimestamp":1741366689,"startTime":"0","endTime":"0","summary":"Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2021/12/Stock-moderna-12-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2021/12/Stock-moderna-12-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/moderna-stock-executives-buy-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE00BBT3K403.USD","BK4007","BK4550","BK4585","SG9999013999.USD","BK4547","IE00B19Z3581.USD","LU1894683348.USD","IE00BLSP4452.SGD","BK4533","LU0321505439.SGD","LU1829250122.USD","LU1057294990.SGD","IE000M9KFDE8.USD","BNTX","SG9999011175.SGD","GSK","LU0122379950.USD","LU0456855351.SGD","LU1894683264.USD","LU0868494617.USD","SG9999002224.SGD","PFE.AU","LU0234572021.USD","LU0058720904.USD","LU0985481810.HKD","GSK.UK","BK4534","SGXZ57979304.SGD","BK4581","BK4592","LU0225771236.USD","BK4501","LU1066053197.SGD","BK4599","LU1066051498.USD","MRNA","NVAX","SG9999001176.USD","BK4548","BK4139","BK4568","BK4551","SG9999001176.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","BK7095","IE00BLSP4239.USD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2517374164","title":"Moderna call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2517374164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517374164?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:25","pubTimestamp":1741361151,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Moderna (MRNA) with 25,737 calls trading, 1.2x expected, and implied vol increasing almost 4 points to 82.07%. Jan-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-call-volume-above-normal-and-directionally-bullish-14?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-call-volume-above-normal-and-directionally-bullish-14?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4551","BK4533","BK4588","BK4548","BK4585","BK4501","BK4532","BK4534","MRNA","BK4568"],"gpt_icon":0},{"id":"2517439580","title":"Neumora Therapeutics Shares Fall 13.8% After Johnson & Johnson Stops Studies of Rival Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517439580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517439580?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:30","pubTimestamp":1741357858,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1057294990.SGD","LU2468319806.SGD","JNJ","IE00BSNM7G36.USD","LU1732800096.USD","NMRA","SG9999002232.USD","LU0345769631.USD","LU1066051811.HKD","LU1066053197.SGD","LU0882574055.USD","LU1244550577.SGD","LU1894683348.USD","LU1032466523.USD","LU0912757837.SGD","IE00BJJMRZ35.SGD","BK4504","LU0114720955.EUR","LU0320765646.SGD","LU1430594728.SGD","LU2430703095.HKD","IE00B1BXHZ80.USD","IE0002141913.USD","LU0122379950.USD","LU1221951129.SGD","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","BK4559","BK4568","LU0795875169.SGD","LU1059921491.USD","LU1244550494.USD","IE00B4R5TH58.HKD","LU2129689431.USD","BK4532","LU2129689514.USD","IE00B19Z3B42.SGD","LU1718418525.SGD","LU1280957306.USD","BK4534","LU0345770993.USD","IE00BFTCPJ56.SGD","LU2505996509.AUD","LU2089984988.USD","LU0795875086.SGD","LU1506573853.SGD","LU1935042991.SGD","IE0002270589.USD","LU1267930813.SGD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2517243109","title":"Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2517243109","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517243109?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:03","pubTimestamp":1741356230,"startTime":"0","endTime":"0","summary":"On Friday, Johnson & Johnson  decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor  antagonist, as an adjunctive treatment for major depressive disorder .The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified.In January, Neumora Therapeutics, Inc.’s released data from the Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder.The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.Navacaprant, like aticaprant, is a kappa opioid receptor antagonist. Johnson & Johnsonsays it continues to build on its leadership in Neuroscience.In January, the healthcare giant agreed to acq","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-stops-stage-depression-140350234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0012050646.USD","LU2468319806.SGD","BK4007","LU1244550221.USD","LU1032955483.USD","BK4534","LU0795875086.SGD","IE0002141913.USD","JNJ","LU1674673428.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","NMRA","LU0058720904.USD","LU1059921491.USD","LU0882574055.USD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4568","LU0345769128.USD","LU1221951129.SGD","LU2347655156.SGD","LU0203345920.USD","SSI","LU0203347892.USD","LU2129689605.HKD","LU1057294990.SGD","LU2592432038.USD","IE00BVYPNW00.USD","LU0640476718.USD","SG9999002232.USD","LU1023059063.AUD","LU1066053197.SGD","LU2089984988.USD","LU0889566641.SGD","IE00BDGV0183.EUR","LU1778281490.HKD","IE000M9KFDE8.USD","LU2505996509.AUD","LU0114720955.EUR","IE00B7SZLL34.SGD","BK4504","BK4588","ITCI","LU2129689514.USD","LU2129689431.USD","SG9999001440.SGD","IE0002270589.USD","LU0234570918.USD","IE0034235303.USD"],"gpt_icon":0},{"id":"2517433745","title":"Neumora Therapeutics Shares Down 11.2% Premarket After Johnson & Johnson Stops Studies of Rival Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517433745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517433745?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:58","pubTimestamp":1741355935,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1929549753.HKD","LU1061106388.HKD","LU0114720955.EUR","IE00BSNM7G36.USD","IE00B4R5TH58.HKD","LU1732799900.SGD","BK4559","IE00B2B36J28.USD","LU0345769631.USD","LU0203347892.USD","LU1074936037.SGD","JNJ","LU1066053197.SGD","LU1914381329.SGD","IE00BFTCPJ56.SGD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU0792757196.USD","LU2112291526.USD","LU0203345920.USD","LU1162221912.USD","SG9999001440.SGD","BK4007","LU1585245621.USD","SG9999002232.USD","LU1506573853.SGD","IE00B3PB1722.GBP","LU1023059063.AUD","LU1244550494.USD","NMRA","LU1894683264.USD","LU0882574055.USD","BK4568","LU0289739699.SGD","LU1244550221.USD","LU1196500208.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0058720904.USD","IE00B42XCP33.USD","LU0345770308.USD","LU1280957306.USD","IE00BVYPNW00.USD","LU0466842654.USD","LU0345770993.USD","LU2129689431.USD","BK4550","IE00B19Z3B42.SGD","LU1032466523.USD","LU1066051225.USD"],"gpt_icon":0},{"id":"2517313024","title":"Stock Market Drama Highlights Trump's Game Of Chicken With Economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517313024","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517313024?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352425,"startTime":"0","endTime":"0","summary":"Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/etfs-and-funds/mutual-funds/stock-market-drama-highlights-trumps-game-of-chicken-with-economy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU2108987350.USD","MCD","UBmain","LVHD","GOVT","BND","IBM","JNJ","EUFN","US6M.BOND","VTI","ZFmain","SHY","DRAG","ZBmain","US10Y.BOND","SHLD","IEI","TNmain","IEF","US5Y.BOND","LU1917777945.USD","LU0320765646.SGD","LU1244550494.USD","LU1880398554.USD","BK4568","LU0289739699.SGD","SG9999014575.USD","VTI.AU","IE00BJTD4V19.USD","LU2362541513.USD","US2Y.BOND","LU1244550221.USD","US30Y.BOND","FDN","FDL","LU0058720904.USD","CQQQ","US3Y.BOND","ZTmain","LU0345770993.USD","US12M.BOND","US7Y.BOND","LU1267930730.SGD","IYK"],"gpt_icon":1},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","LU1066051498.USD","BK4018","LU2129689431.USD","LU2129689514.USD","BK4139","BK4558","LU2552382215.SGD","PD","PG","ARDS","IE00BLSP4239.USD","SG9999002232.USD","LU1868836914.USD","LU0234572021.USD","USA","BK4568","LU1066053197.SGD","SG9999014542.SGD","SG9999001440.SGD","LU0094547139.USD","LU1169589451.USD","SG9999014575.USD","BK4504","BK4535","BK4181","LU0061475181.USD","LU1929549753.HKD","BNTX","BK4534","BK4559","IE00B3T34201.USD","IE00BWXC8680.SGD","LU1868837136.USD","IE00BBT3K403.USD","LU0868494617.USD","LU1162221912.USD","LU1430594728.SGD","SG9999015341.SGD","LU1868837300.USD","SG9999015358.SGD","LU1585245621.USD","PK","SG9999002224.SGD","LU1868836591.USD","BK4581","SG9999014567.USD","LU0234570918.USD","BK4533","LU0689626769.HKD"],"gpt_icon":0},{"id":"2517633487","title":"Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2517633487","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517633487?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:55","pubTimestamp":1741352147,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free sur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4585","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4007","LU0320765992.SGD","LU2417539215.USD","LU0109394709.USD","BK4588","LU2236285917.USD","BK4568","AZN"],"gpt_icon":0},{"id":"2517388304","title":"AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517388304","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517388304?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:54","pubTimestamp":1741352061,"startTime":"0","endTime":"0","summary":"On Friday, AstraZeneca Plc  released high-level results from the MATTERHORN Phase 3 trial evaluatingImfinzi as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction  cancers.The trial showed that perioperative treatment with Imfinziin combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival .Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal junction  cancers.A strong trend was observed for the secondary endpoint of overall survival  in favor of theImfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.Gastric cancer is the fifth leading cau","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-based-regimen-shows-125421014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","BK4588","LU2456880835.USD","OS","AZN","SSI","LU2462157665.USD","LU0889565916.HKD","BK4568","BK4585","BK4097"],"gpt_icon":0},{"id":"2517480086","title":"2 Dependable Dividend Stocks That Can Pay You for Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480086","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480086?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:15","pubTimestamp":1741349700,"startTime":"0","endTime":"0","summary":"Medtronic and Abbott Labs have raised their dividends for a combined 99 years.Both healthcare giants have solid operations and excellent long-term prospects.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/07/2-dependable-dividend-stocks-that-can-pay-you-for/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU2089984988.USD","BK4592","LU0170899867.USD","SG9999004303.SGD","LU2468319806.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4533","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1721429402.USD","SG9999002232.USD","ABT","IE00B4R5TH58.HKD","LU1989763690.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","LU2133065610.SGD","BK4082","LU1057294990.SGD","LU1691799644.USD","LU1989763427.SGD","IE0002141913.USD","SG9999002224.SGD","LU1023059063.AUD","LU0122379950.USD","LU1721429741.USD","BK4585","LU2237957902.USD","BK4588","IE0009355771.USD","LU2237957811.SGD","BK4568","SGXZ23171101.USD","LU0868494617.USD","LU1914381329.SGD","LU2112291526.USD","BK4566","BK4504","BK4581","LU0266013472.USD"],"gpt_icon":0},{"id":"2517484555","title":"AstraZeneca announces MATTERHORN trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484555","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484555?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:07","pubTimestamp":1741349232,"startTime":"0","endTime":"0","summary":"Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-matterhorn-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-matterhorn-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU0889565916.HKD","LU2456880835.USD","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2517816524","title":"Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2517816524","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517816524?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"Delivered Adjusted EBITDA growth through strong execution and cost discipline Continued progress on the transformation to enhance capabilities and increase operating efficiencies Management expects gr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038854/0/en/Advantage-Solutions-Reports-Fourth-Quarter-and-2024-Results-Transformation-Initiatives-Continue-to-Strengthen-the-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","BK4551","BK4588","BK4535","BNTX","BK4139","BK4548","ADV","BK4568","BK4585"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","BK4582","BK4132","FLOT","LU2417539215.USD","OS","ALK","AZN","BK4007","LU0320765992.SGD","BK4588","TEN","BK4008","HCC","BK4213","BK4124","BTC","BK4144","LU2462157665.USD","BK4585","LU0889565916.HKD","BK4568","LU2456880835.USD","VOD","BK4500","LU2236285917.USD","HSCT","LU0109394709.USD","BK4532","BK4097","BK4006","CRT","LU1829250122.USD"],"gpt_icon":0},{"id":"2517113485","title":"AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113485","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113485?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:12","pubTimestamp":1741345966,"startTime":"0","endTime":"0","summary":"Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","III","LU0889565916.HKD","LU2456880835.USD","BK4134","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0}],"pageSize":16,"totalPage":20,"pageCount":2,"totalSize":307}]}}